CSL tumbled to a six-month low on Monday as investors fled healthcare stocks after US President-elect Donald Trump named avowed vaccine sceptic Robert F. Kennedy jnr to lead the US Health Department.

Australia’s largest pharmaceutical group, which has manufactured seasonal influenza vaccines since the 1940s, is trading below $273 for the first time since April. The shares are down more than 4 per cent since Mr Kennedy’s nomination was announced on Friday.